1. Cabbacis will attend Q3 Virtual Investor Summit on September 16-17, 2025. 2. CEO Joseph Pandolfino will present company milestones and commercialization strategies. 3. Cabbacis recently received a U.S. patent for new vaporizer pods. 4. Company aims to provide harm-reduction alternatives in the tobacco sector. 5. iBlend brand products may benefit from FDA's proposed nicotine cap regulation.
Cabbacis' recent innovations and patents position it favorably under upcoming regulations, similar to how Juul's market introduction spurred interest in e-cigarettes.
The article discusses significant corporate developments and regulatory context directly affecting CABI's business and market positioning.
With FDA regulations potentially enhancing market demand for harm-reduction products, Cabbacis may see gradual but sustained growth.
Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on harm-reduction products being developed under the iBlend™ brand name, today announced that management will attend the upcoming Q3 Virtual Investor Summit on September 16th and 17th 2025.
Joseph Pandolfino, Chief Executive Officer of Cabbacis, is scheduled to present at the conference, as well as host one-on-one virtual meetings with institutional investors throughout the event as follows:
Q3 Virtual Investor Summit Presentation
Date: Tuesday, September 16, 2025
Time: 10:00 a.m. Eastern time
Webcast: https://investorsummitgroup.com/presentor/track-2-cabbacis/
Joseph Pandolfino commented: "We are pleased to participate in the Q3 Virtual Investor Summit and look forward to highlighting our recent milestones, including the granting of a U.S. patent No. 12,349,724 for our novel vaporizer pods and the qualification of our Regulation A Tier 2 offering. With these important steps, we are advancing our commercialization strategy and reinforcing our commitment to providing harm-reduction alternatives in the tobacco sector. This conference provides an excellent platform to engage with investors and discuss our progress, execution and growth outlook."
Registration is required for conference participation. For more information or to schedule a meeting with management, please contact MZ Group at CABI@mzgroup.us.
About Cabbacis
Cabbacis (OTCQB:CABI) is focused on commercializing groundbreaking, patented harm-reduction tobacco products for the world's one billion smokers. Led by its flagship iBlend™ reduced-nicotine cigarettes and vaporizer pods in development, the Company is well positioned ahead of the proposed FDA rule to cap the nicotine content in all U.S. cigarettes. iBlend™ predominately contains tobacco combined with non-intoxicating hemp to assist in smoking or vaping less, transitioning to less harmful tobacco products, and/or increasing quit attempts. The Company also plans to commercialize reduced-nicotine tobacco cigarettes and little cigars without hemp and vaporizer pods with conventional-nicotine tobacco and hemp.
In a recent clinical trial reported by the Company, Cabbacis cigarettes were highly rated for satisfaction and significantly reduced cravings for usual brand cigarettes. Cabbacis holds a global patent portfolio of 35 issued patents and various pending patent applications – primarily covering tobacco-hemp combinations in cigarettes and vaporizer pods – across key markets including the United States, Europe, China, India, Japan, Indonesia, Russia, South Korea, Canada, Australia, New Zealand, Mexico and Brazil – where approximately two-thirds of the world's smokers collectively reside.
To learn more, please visit cabbacis.com or follow us on LinkedIn or X.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the federal securities law. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "foresee," "intend," "likely," "may," "objective," "potential," "plan," "predict," "project," "seek," "should," "will" and similar words or phrases and their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual outcomes or results could differ materially for a variety of reasons. Factors that could cause actual results to differ materially are described in "Risk Factors" in our Regulation A Offering Circular qualified by the SEC on June 3, 2025 and in our Annual Report on Form 1-K for the period ended December 31, 2024 filed with the SEC. We undertake no responsibility to publicly update or revise any forward-looking statement except as required by applicable law.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the Company's securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of that state or jurisdiction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909593597/en/
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(949) 259-4987
CABI@mzgroup.us
www.mzgroup.us